Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics? by Brunel, A.S. & Guery, B.
Review article: Biomedical Intelligence | Published 22 November 2017 | doi:10.4414/smw.2017.14553
Cite this as: Swiss Med Wkly. 2017;147:w14553
Multidrug resistant (or antimicrobial-resistant)
pathogens - alternatives to new antibiotics?
Brunel Anne-Sophie, Guery Benoit
Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
Summary
For the last few decades, multidrug resistance has be-
come an increasing concern for both Gram-positive and
Gram-negative bacteria. The number of new molecules
has dramatically decreased and antibiotic resistance is
now a priority in the international community. Facing this
new threat, a large number of new as well as “old” solu-
tions are now being discussed in the medical community
to propose an alternative to antibiotic treatments. A first
option is to potentiate the effect of existing molecules
through combinations to circumvent the individual mole-
cule resistance. The second option is to neutralise either
the infectious agent itself or its by-products using specific
antibodies. A third option is to use the pathogen signaling
mechanism and inhibit the production of virulence factor
through quorum sensing inhibition. A fourth pathway
would be to interact with the patient’s microbiota using ei-
ther probiotics or faecal transplantation to modulate the in-
nate immune response and improve response to the infec-
tious challenge, but also to act directly against colonisation
by resistant bacteria by replacing the flora with suscepti-
ble strains. The last option is to target the bacteria using
phage therapy. Phages are natural viruses that specifically
infect target bacteria independently of any antibiotic-sus-
ceptibility profile. In this review, we will discuss each of
these options and provide the scientific rationale and the
available clinical data. In the majority of cases, these treat-
ments represent an interesting approach but not the ul-
timate solution to multiresistance. Well-performed clinical
trials are still missing and the major priority remains to pro-
mote good use and appropriate stewardship of antibiotics
to decrease resistance.
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Introduction
With the appearance of penicillin, antibiotics became one
of the most important revolutions in infectious-disease
management. The medication was followed in subsequent
decades by a growing number of new agents. The most ob-
vious consequence was the rapid emergence of resistance
associated with the use of each new agent. Today, the num-
ber of antiobiotic molecules is reaching a plateau, but resis-
tance continues to grow. In 2013, the United States Centers
for Disease Control (CDC) published a report outlining the
top 18 drug-resistant threats to the USA. Among these,
carbapenem-resistant Enterobacteriaceae were classified
as urgent, and multidrug-resistant Acinetobacter, extended
spectrum Enterobacteriaceae, vancomycin-resistant Ente-
rococcus and multidrug-resistant Pseudomonas aerugi-
nosa were qualified as serious threats. Recently, the Eu-
ropean survey of carbapenamase-producing Enterobacte-
riaceae (EuSCAPE) performed a prospective multination-
al study on 2703 clinical isolates involving 455 sentinel
hospitals in 36 countries [1] (85% K. pneumoniae and
15% E. coli). The results showed that 850/2301 (37%)
K. pneumoniae and 77/402 (19%) E. coli were carbapen-
emase producers (KPC, NDM, OXA-48 like, or VIM).
Similarly, for extended-spectrum beta-lactamase, a retro-
spective study over 5 years was performed in a French
hospital and showed that incidence significantly increased
from 5.2% of all positive E. coli blood cultures in 2005
to 13.5% in 2009 [2]. A meta-analysis studying faecal
colonisation among healthy individuals included 66 stud-
ies on 28 909 healthy individuals, and showed a pooled
prevalence of colonisation with extended-spectrum beta-
lactamase producers reaching 14% with an annual-increase
trend of 5.38% [3]. Finally, in a very elegant review, Bas-
setti et al. reported that colistin resistance could cause up
to 10 million deaths per annum by 2050 and cost an excess
of USD 100 trillion to the world’s economy [4].
If antibiotic stewardship and good use is the logical answer
to resistance, we are now facing infections with a limited
number of therapeutic options, and alternative treatments
must be developed. These options are either based on spe-
cific targets on the bacteria, or designed to improve the
host response to the infectious injury. In this review we
will discuss these therapeutic options and provide the sci-
entific and clinical data available.
Combination of antibiotics
The spread of multidrug-resistant, extensively drug-resis-
tant and pan-drug-resistant Gram-negative pathogens is
causing an unprecedented public health crisis.
Pseudomonas aeruginosa, Acinetobacter baumanii, and
Klebsiella pneumoniae are the most common pathogens
associated with multiresistance. Multidrug-resistant
(MDR) Gram-negative bacilli (GNB) are resistant to anti-
pseudomonal β-lactams, carbapenems, fluoroquinolones
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and aminoglycosides, limiting therapeutic options in cases
of serious infection that are seen most often in critically ill
patients with comorbidities.
The non-negligible risk of inducing further resistance by
the use of last-resort antibiotics and the limited current
therapeutic options [5] led to the revival of two ‘old’ an-
tibiotics 10 years ago: colistin [6, 7] and fosfomycine [8].
Intravenous colistin is a cationic peptide with bactericidal
activity against P. aeruginosa and other GNB. Several
studies have demonstrated in vitro synergy between col-
istin and β-lactams, rifampicin or fosfomycin against MDR
GNB. Few case reports have documented the success of
these salvage-treatment combinations containing colistin
[7, 9–15]. Although the use of colistin monotherapy has
been identified as a risk factor for the development of re-
sistance during treatment [16], no clear survival benefit of
combinations containing colistin over colistin monothera-
py has been demonstrated [11, 17]. But a better infection
outcome was observed in patients treated with colistin
alone or colistin/meropenem than those receiving colistin
in combination with other antibiotics [11]. For A. bau-
manii, no effect of the combinations colistin/rifampicin or
colistin/fosfomycin on mortality has been shown in three
randomised controlled trials (RCTs) [17]. Two RCTs are
currently being performed to compare colistin alone with
colistin/meropenem for the treatment of severe infections
caused by carbapenem-resistant GNB [18].
Fosfomycin could also be a good therapeutic alternative
for the treatment of MDR GNB infections due to its bac-
tericidal activity and the absence of cross resistance with
other antibiotics. Fosfomycin was synergistic in vitro in
combination with β-lactams, colistin, aminoglycosides or
tigecycline against MDR P. aeruginosa and CPE [8, 19],
and effective in treating severe infections in association
with these antibiotics in a few studies [8, 19–22]. However,
only 30.2% of the MDR P. aeruginosa isolates were sus-
ceptible to fosfomycin, which limits the use of fosfomycin
in empirical therapy [21].
Tigecycline is potent in vitro against MDR A. baumanii
and CPE and has been utilised off-label in critically ill pa-
tients [5, 20]. Combination therapy and higher dosage are
suggested due to disadvantageous pharmacokinetic para-
meters [5, 20] even though the level of evidence is low.
With the limitations of non-RCTs, combinations contain-
ing high-dose and prolonged infusion meropenem in order
to prevent treatment failure have demonstrated a survival
benefit in CPE infections if the minimum inhibitory con-
centration (MIC) is ≤8mg/l [23–25], and even if the MIC
is ≥16mg/l [26] compared to other combinations, but with
a close monitoring of optimal meropenem exposure [20].
New drugs for MDR P. aeruginosa (ceftazolane-tazobac-
tam and ceftazidime-avibactam) and for selected carbapen-
emase-producing Enterobacteriaceae (CPE) (ceftazidime-
avibactam) are already available. These new drugs are ap-
proved for complicated intra-abdominal infections and uri-
nary tract infections. They are effective and produce min-
imal side effects. In a retrospective study including 35 pa-
tients with carbapenem-resistant P. aeruginosa infections,
87% of the isolates tested (n = 26/30) were susceptible to
ceftazolane-tazobactam including 19 of the 23 isolates re-
sistant to all other β-lactams. ceftazolane-tazobactam was
successful in 26 patients (74%), mostly prescribed in
monotherapy (77%), and failure was observed when iso-
lates had MICs ≥8 μg/ml [27]. For CPE infections, the clin-
ical experience of ceftazidime-avibactam is currently lim-
ited to case series [20, 28] with promising clinical results,
but the question of monotherapy or combination remains
unclear.
Novel antibiotic compounds targeting MDR GNB are un-
der investigation, including meropenem-vaborbactam,
imipenem-relebactam, plazomicin, cefiderocol and erava-
cycline [5, 20, 29]. Among these, meropenem-vaborbac-
tam and plazomicin have already shown promising results.
The best available treatment against MDR GNB is un-
known. Combinations seem attractive when looking at in
vitro results or the lower mortality rates compared to
monotherapy for the treatment of severe CPE in retrospec-
tive cohort studies [23–25, 30, 31], but these results are to
be weighed cautiously and RCTs are urgently needed be-
fore a formal recommendation. Most of the data are de-
rived from in vitro studies with limited in vivo translation
[32], and from observational non-randomised studies with
low-level evidence and high risk of bias. There is likewise
no in vivo evidence that combination therapy prevents an-
tibiotic resistance. Combination therapy may therefore be
an option in CPE severe infections or, as an expert panel
has proposed, in critically ill patients [5, 20] while keeping
in mind the downside of the combination such as more side
effects and the pending results of RCTs (NCT01597973
and [18]). For non-critically ill patients without severe in-
fections, RCTs are needed to evaluate the benefits and
costs of antibiotic combination, and impact on resistance
induction.
If Gram-negative pathogens are a clear challenge, the man-
agement of multidrug-resistant Enterococcus infections is
also complicated because of resistance to ampicillin and
vancomycin, which are two of the traditionally most useful
antibiotics. Linezolide and daptomycin represent interest-
ing options. Linezolid, a bacteriostatic agent, is the only
drug specifically approved by the Food and Drug Admin-
istration (FDA) for the treatment of vancomycin-resistant
Enterococcus (VRE) bacteraemia. Daptomycin, a lipopep-
tide antibiotic with a rapid bactericidal concentration ac-
tivity against enterococci, has also been an option. Three
metaanalyses compared linezolid to daptomycin alone in
the treatment of VRE bacteraemia, and all three suggested
a survival benefit with the use of linezolid [33–35]. How-
ever, the methodology of the studies has been questioned
[36, 37], with speicifc focus on the inadequate dose of dap-
tomycin (<6 mg/kg/day) [35, 38]. Furthermore, a large ret-
rospective cohort study of VRE bacteraemia showed that
daptomycin was superior to linezolid, which was associat-
ed with higher microbiologic failure rates, higher 30-day
mortality and more treatment failure [37]. In this study,
daptomycin was even relatively under-dosed (6 mg/kg/
day). Finally, Chuang et al., in a prospective cohort study,
showed that linezolid conferred no survival benefit com-
pared to high doses of daptomycin (≥9 mg/kg/day) [38],
but that high doses of daptomycin was associated with
lower mortality compared with low doses, as already de-
scribed by Britt et al. [39].
The emergence of daptomycin-resistant strains during ther-
apy with low doses of daptomycin monotherapy causing
clinical failure [40] led to the use high doses of daptomycin
[41–43], but also combination with other antibiotics [44].
Association with ampicillin could be interesting because
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ampicillin can alter the surface charge of these strains by
allowing the cationic daptomycin/calcium complex to bind
more effectively to the cell wall [45]. Ceftaroline also
has significant effects on growth rate in vitro as well as
causing biophysical changes on the cell surface of VRE
that can potentiate the activity of daptomycin and innate
cationic host defense peptides, even if Enterococci are
ceftaroline resistant [46]. In vitro synergy of daptomycin
plus rifampicin or tigecycline has also been reported [43].
Nevertheless, only a few case reports have documented
successful combinations of daptomycin with other antibi-
otics [44, 47] and these synergies observed in vitro have
not been clinically validated by appropriate trials. More-
over, increased daptomycin use has recently been associat-
ed with resistance development in E. faecium bacteraemia
over time even when combined with β-lactam antibiotic
[48]. Clinicians should be aware of the risk of the emer-
gence of daptomycin resistance and should monitor dapto-
mycin MICs of Enterococci during treatment.
Despite the development of novel drugs with activity
against VRE, such as oritavancin and tedizolid, the best
therapeutic strategy to treat VRE bacteraemia remains to
be established and randomized clinical trials including
combination therapies are urgently needed.
Vancomycin is commonly used to treat serious methicillin-
resistant Staphylococcus aureus (MRSA) infections. Treat-
ment failures have been described, most often in associ-
ation with increased vancomycin MICs: vancomycin-in-
termediate S. aureus (VISA; MICs 4–8 μg/ml), heteroge-
neous VISA (hVISA; MICs in the susceptible range), or
exceptionally VRSA (MICs >8 μg/ml). While the IDSA
recommends monotherapy with vancomycin (level of evi-
dence A, class of recommendation I) or daptomycin (level
of evidence A, class of recommendation II) in cases of
MRSA bacteraemia and endocarditis [49], evidence to sug-
gest the need for rapid reduction of the bacterial inoculum
and to prevent the emergence of resistance in combination
therapy against these infections is growing.
Several studies have shown in vitro and in vivo the utility
of the association of daptomycin and antistaphylococcal
β-lactams, mainly oxacillin, in MRSA bacteraemia to en-
hance bacterial clearance. This is especially the case in
daptomycin-non-susceptible strains (seesaw effect) [50],
and prevents the emergence of daptomycin-resistant strains
[51, 52]. The new cephalosporin, ceftaroline, is also inter-
esting for its intrinsic activity against MRSA and its effica-
cy alone against daptomycin-non-susceptible strains in vit-
ro and in animal models. The combination of daptomycin
and ceftaroline was used successfully in salvage thera-
py after emergence of daptomycin-non-susceptible MRSA
[53, 54], but also in a recent case of ceftaroline-resistant
daptomycin-tolerant hVISA endocarditis [55].
Synergy in vitro between vancomycin and anti-staphylo-
coccal β-lactams against MRSA, including oxacillin [56,
57], ceftaroline [57, 58], piperacillin-tazobactam [56] has
been demonstrated recently even on hVISA or VISA, and
the association between vancomycin and ceftaroline was
used successfully to clear persistent daptomycin-non-sus-
ceptible MRSA bacteraemia [58].
There is limited experience of fosfomycin in combination
with daptomycin, but some cases of MRSA bacteraemia or
endocarditis have been successfully treated with this com-
bination [59–61]. On the contrary, daptomycin in combi-
nation with rifampin or gentamicin has not been associated
with a better response in an experimental model of MRSA
endocarditis [62].
Although these results are in vitro data or case reports,
a combination of antibiotics often seems effective for the
treatment of serious MRSA infections. It is important to
test all MICs to choose the best combination. In a pilot
study by Davis et al. [63], combining flucloxacillin with
vancomycin was able to shorten the duration of MRSA
bacteraemia. Multicentre randomised controlled clinical
trials are currently being performed to determine whether
the combination of anti-staphylococcal penicillin plus
standard therapy (vancomycin or high-dose daptomycin)
[64] or high-dose daptomycin plus fosfomycin [59], result
in improved clinical outcomes in MRSA infections.
In the era of multiresistance, combination of antibiotics
is commonly used as salvage treatment to treat infections
by extensively drug-resistant and pan-drug-resistant Gram-
negative pathogens, but it is often sub-optimal [65]. An-
tibiotics are used off-label, at a higher dosage, and com-
bined with more than two other antibiotics against a single
pathogen, with proven synergy only in vitro [65]. Despite
the results of observational studies, no RCTs have con-
firmed the advantage of combination therapy for the man-
agement of MDR infections. International collaboration is
urgently needed to evaluate the survival benefit and the
risk of resistance induction by performing RCTs to provide
harmonised guidelines and ensure optimal use of our last
therapeutic options available.
Antibodies
On 4 December 1890, Von Behring and Kitasato published
the first paper using the blood of rabbits to neutralise
tetanus and diphteria toxins [66]. Serum therapy was af-
terwards largely used in infectious diseases like pneumo-
coccal pneumonia, meningococcal meningitis, dysenteria,
or erysipelas [67]. This treatment was then abandoned for
antimicrobial chemotherapy because administration of sera
was associated with fever, allergic reactions and serum
sickness. However, serum therapy persisted for a limited
number of indications like hepatitis, measles, or toxin-in-
duced diseases like tetanus, diphtheria and botulism.
If serum therapy was the first step, the improvement of the
knowledge in immunology led to the development of spe-
cific antibody administration directed against a pathogen
or a virulence factor. Two types of products are used. These
are pooled polyclonal human immunoglobulins targeting
several epitopes, or monoclonal antibodies focused on one
specific target. However, administration of immunoglobu-
lins or monoclonal antibodies does not stimulate the im-
mune system so the effect does not persist over time.
Antibodies represent a classical approach in infectious dis-
eases that is clearly not directly related to resistance. How-
ever, identifying determinants that are relatively conserved
between strains, whether or not associated with virulence
factors, could potentially be interesting in the context of
multiresistance.
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Antibodies in infectious diseases
Antibodies in sepsis
Facing multidrug resistance, an interesting approach could
be to target the host’s immune response, although this is of
course specific to the type of resistance itself and the ef-
fect could therefore be limited in cases of total antibiotic
resistance. Cytokines represent a normal response to infec-
tion but excessive production is associated with organ and
tissue damage. For many decades sepsis was analysed as
a hyperinflammatory syndrome, but more recently sever-
al authors have suggested that sepsis is a dynamic process
that is both a pro-inflammatory state to anergy and im-
munoparalysis [68]. Immunotherapy has been largely ex-
plored in sepsis with a very large number of studies trying
to block the effect of mediators or signaling molecules.
Many studies have evaluated the potential role of intra-
venous immunoglobulins in sepsis with a rationale based
on the neutralisation of endotoxin, and immunomodulation
with a reduced production of pro-inflammatory mediators
and increased production of anti-inflammatory mediators.
Two meta-analyses suggested that intravenous im-
munoglobulins reduced mortality in adults with sepsis [69,
70], but the more recent Cochrane analysis drew on 43
studies to show that this benefit disappeared when consid-
ering only the trials with low risk of bias [71]. Recently, in
2014, Cavazzuti et al. studied the influence of early thera-
py with IgM-enriched polyclonal immunoglobulin in sep-
tic shock and showed a 21.1% mortality reduction in the
group that received IgM [72].
Another approach could be to target bacterial endotoxin.
In 1991, Ziegler showed that HA-1A, a human monoclonal
IgM antibody that binds to the lipid A domain of endo-
toxin, could decrease mortality in patients with Gram-neg-
ative bacteraemia and shock at entry [73]. These results
were not confirmed in a second trial [74].
The first milestone in the potential role of cytokine inhibi-
tion was published in 1987. Tracey et al. showed that ad-
ministration of neutralising monoclonal anti-tumor necro-
sis factor antibody administered to baboons before bacteri-
al challenge protected against shock [75].
Based on this initial study, a number of clinical trials were
carried out and showed no significant clinical benefit [76].
An interesting analysis was performed in 2005 by Lorente
and Marshall. This underlines the major discrepancies be-
tween the studies and the models used to evaluate the ef-
fect. Global neutralisation of tumour necrosis factor-alpha
(TNFα) is associated with the impairment of antimicrobial
defenses [77].
Using the same initial rational, interleukin (IL)-1 inhibitor
or antagonists of the IL-1 receptor led to comparable re-
sults. With a cohort of 893 patients with sepsis syndrome,
recombinant human interleukin 1 receptor antagonist did
not modify the survival time compared to the placebo [78],
and a confirmatory study with 696 patients was published
three years later [79]. Since these early studies, antagonis-
ing the activities of pro-inflammatory cytokines has failed
to provide clinical benefit despite evidence to the contrary
obtained from animal studies. In 2013, eritoran, a syn-
thetic lipid A antagonist blocking lipopolysaccharide from
binding at the TLR 4 receptor, failed to improve mortality
at 28 days with no differences even in pre-specified sub-
groups [80]. One of the most promising pathway recently
proposed is related to T-cell exhaustion observed in sep-
sis. Programmed cell death 1 (PD-1) is induced after T-
cell activation. PD-1 is a negative co-stimulatory molecule
linked to T-cell exhaustion in sepsis [81]. Brahmamdam
et al. showed in a cecal ligation peritonitis model in mice
that anti-PD-1 antibody prevented sepsis-induced deple-
tion of lymphocytes, blocked apoptosis, and improved sur-
vival [82]. The clinical evaluation is yet to be performed.
Other targets could also be proposed like the migration
inhibitory factor (MIF) [83] or the high mobility box-1
(HMGB-1) [84] considered as late cytokines. One of the
approaches discussed for the future would be to propose a
tailored treatment targeting more than one cytokine based
on the patient’s profile (genetic polymorphism).
Globally all these new therapeutics and potential pathways
to explore are of course interesting in the context of multi
resistance where the host response is critical to the
pathogen clearance. However, this is clearly not specific
to resistance itself and actually developed for susceptible
pathogens.
Virulence factors
Targeting virulence factors has been proposed for various
bacteria, and a good example is Staphylococcus aureus. A
chimerised monoclonal antibody against lipoteichoic acid
protective in animal models for coagulase negative staphy-
lococci and Staphylococcus aureus bacteraemia, it showed
a good safety profile with good activity at 3 and 10 mg/
kg in healthy adults [85]. A phase I/II double-blind place-
bo-controlled study evaluated the preventive effect of this
molecule (pagibaximab) for staphylococcal bloodsteam in-
fections in very low birth weight neonates [86]. The num-
ber of patients was not sufficient to reach a conclusion
but the authors observed sustained plasma anti-lipoteichoic
acid levels following the second dose [86]. A phase II
study in the same population reached similar conclusions
with a trend for efficacy but no definitive conclusions re-
lated to a small number of patients [87].
Tefizumab is a humanised monoclonal antibody that binds
to the surface-expressed adhesion protein clumping factor
A [88]. The development was stopped after a phase II ran-
domised multicentre study where the molecule failed to
show a major clinical effect [89]. Similarly, Altastaph, a
polyclonal anti-Staphylococcus aureus capsular polysac-
charide immunoglobulin showed only slight efficacy and
was not further developed after two phase-II trials [90,
91]. Several other approaches are currently being explored
that target the alpha-hemolysin, and the alpha-toxin con-
served antigens, Luks-PV, or the Panton-Valentine leuko-
cidin [92–96].
P. aeruginosa is a Gram-negative bacterium associated
mainly with respiratory and urinary-tract infections. This
pathogen is largely associated with ventilator-associated
pneumonia with a high morbidity and mortality [97]. An-
other potential target is the apparatus associated with the
production of virulence factor like the type-three secretion
system (TTSS). Pseudomonas produces a large number of
virulence factors [98] but TTSS is probably one of the
most sophisticated systems [99–101]. A part of the TTSS,
PcrV, belongs to the translocon allowing the secretion of
four exotoxins: Exo U, S, T, and Y. In a seminal paper
published in 1999, Sawa et al. showed the major role of
PcrV in Pseudomonas-induced mortality [102]. These re-
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sults were also confirmed in a different model [103]. The
key role of the TTSS was also shown in Pseudomonas
aeruginosa pneumonia-induced septic shock. TTSS toxins
were associated with the decompartimentalisation of the
inflammatory response [104]. Again other authors have
shown comparable results [105, 106]. In 35 patients with
P. aeruginosa pneumonia, Hauser et al. demonstrated that
TTSS expression was associated with poor clinical out-
come (81% of severe diseases with TTSS versus 38%
without TTSS) [107]. A nice review summarises the
knowledge between TTSS and clinical outcome [108].
With these data showing the clinical relevance of the
TTSS, it seemed interesting to develop antibodies directed
against the TTSS. A prospective randomised double-blind
placebo- controlled trial evaluated an anti-PcrV PEGylated
monoclonal antibody in mechanically ventilated patients
colonised with P. aeruginosa [109]. The results showed a
favorable tolerance profile and a reduction of P. aerugi-
nosa pneumonia incidence. Although these results were in-
teresting, there was no further development of this anti-
body.
Another opportunity for immunisation could in combina-
tion with an anti-infective. In a murine model of P. aerug-
inosa acute infection, Song et al. associated monoclonal
antibodies with relevant antibiotics and showed a synergis-
tic effect with an improvement in survival [110]. Against
Stenotrophomonas maltophilia, additive and synergic ef-
fects were obtained by combining anti-efflux pumps anti-
bodies and antibiotics [111].
Some authors also tried to develop bispecific antibodies
with a monoclonal antibody specific to the target pathogen
and cross-linked with a monoclonal antibody specific to
the complement (to activate pathogen clearance). This was
tested with interesting results on several pathogens such as
P. aeruginosa, B. anthracis, and S. aureus [112–114].
In the fungal area, several antibodies have also been stud-
ied. Enfungumab is a genetically recombinant antibody
against heat-shock protein 90 with good activity against
Candida spp [115]. Heat-shock protein has also been re-
ported in Cryptococcus neoformans. Nooney et al. showed
that the combination of amphotericin and enfungumab
were synergic on this pathogen [116]. A phase III study
in invasive candidiasis was conducted on 117 patients, and
a complete response was obtained in 48% of the patients
in the amphotericin group and 84% in the group receiving
amphotericin and enfungumab [117]. Mortality also de-
creased from 18% to 4%. However, in 2006, the Commit-
tee for Medicinal Products for Human Use (CHMP) rec-
ommended the refusal of the marketing authorisation for
the product due to matters of quality and safety concerns.
A variant was then proposed but was not effective (no in-
trinsic fungicidal activity, no synergy with amphotericin)
[118].
Targeting virulence factors is an interesting pathway, but
in most cases, the antibody is directed against only one de-
terminant of virulence. For this reason, and for bacterial as
well as fungal studies, the antibody is associated with an
antibiotic or an antifungal, and killing the bacteria will re-
main a key issue – although blocking virulence may allow
host response to be more efficient.
Quorum sensing
Quorum sensing is a signalling mechanism involving the
exchange of chemical signals in bacterial populations to
adjust the bacterial phenotype to the density of the pop-
ulation. The chemical signals are small molecules called
autoinducers. The autoinducers diffuse freely or actively
and reflect the density of the global population. When a
threshold of concentration is reached, the gene expression
program of the bacterial cells is altered and gene tran-
scription is switched on or off. Autoinducers represent
a large community of molecules including oligopeptides,
like the autoinducing peptides of S. aureus, dihydroxypen-
tanedione derivates like autoinducer-2 of V. harveyi, or
acyl-homoserine lactones in Gram-negative bacteria [119].
In S. aureus, the expression of various virulence factors
is regulated by the cell-density-dependent quorum-sensing
accessory gene (agr) system. Short peptides are used as
signalling molecules, and S aureus encodes four different
allelic autoinducing peptide variants [120]. In Staphylo-
coccus infection, quorum sensing regulates biofilm forma-
tion and toxin production. RNAIII inhibiting peptide has
been shown to inhibit quorum sensing [121]. Recently Si-
monetti et al. evaluated the combined effect of quorum
sensing inhibition with the administration of a new RNAIII
inhibiting peptide derivative associated to tigecycline in a
wound infection model [122]. Their results show that the
combined effect induced a positive interaction in vivo in
this model. Recently, myricetin, a flavonoid, was shown to
decrease the production of several S. aureus virulence fac-
tors independently of the agr quorum sensing system, and
could represent an interesting pathway [123].
Pseudomonas aeruginosa relies on three quorum-sensing
systems: las, rhl and the Pseudomonas quinolone signal.
las and rhl are based on the production of two acyl-ho-
moserine lactones. These auto inducers control a large
number of virulence factors including elastase, alkaline
protease, exotoxin A, rhamnolipides, pyocyanin, lectins
and biofilm [124]. The clinical relevance of the inhibition
of the quorum sensing system has been demonstrated even
with clinical strains [125]. A large number of compounds
have shown potential and could be used to inhibit quorum
sensing like furanones, antibiotics, plant extracts, garlic,
and synthetic inhibitors [126–130].
Besides S. aureus and Pseudomonas aeruginosa, quorum
sensing has been described as a regulator of virulence for
other pathogens like E. coli, Salmonella or Francisella tu-
larensis [119] and is considered as a relevant target to com-
bat bacterial virulence.
Inhibition of the quorum sensing is neither bacteriostatic
nor bactericidal, but should decrease virulence. It must
therefore be emphasised that this approach is an adjunctive
treatment to antibiotics. Even if the concept is now widely
accepted, the number of studies in humans remains very
limited. Azithromycin has been extensively studied in vit-
ro, in animal models, and some data have been obtained
in humans. It was shown that this molecule could block
neutrophil recruitment in Pseudomonas endobronchial in-
fection in mice [131], block quorum sensing-regulated vir-
ulence factor in a chronic model [127], and increase sur-
vival in CF mice [132]. However, the clinical data are not
conclusive. In ventilator-associated pneumonia, no study
showed a difference in mortality [133–135]. Azithromycin
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has also been proposed in cystic fibrosis [136] and COPD
[137]. Although the rationale seems interesting and some
data promising, we still need a well-conducted study to
find the place of quorum sensing inhibition in the era of
multiresistance.
Bacteriocins
Bacteriocins are antimicrobial peptides produced by bacte-
ria. Bacteriocins are small peptides and include ribosomal
or non-ribosomal compounds. They represent a heteroge-
nous group classified into peptides that undergo post-trans-
lational modifications versus unmodified peptides [138].
These molecules present a low toxicity and can have a
wide spectrum. They are usually cationic amphiphiles, and
unstable (susceptibility to proteases). Among all the mole-
cules, only magainin was submitted to the Food and Drug
Administration, but was rejected and no other molecules
are currently proposed for humans [139]. In the future,
brilacidin is one of the lead components developed from a
series of small molecules with potent activity on a broad
range of drug-susceptible and multidrug resistant Gram
positive and negative bacteria. Mensa et al. showed that
Brilacidin could cause membrane depolarisation to an ex-
tent comparable to daptomycin [140]. Other molecules
were evaluated such as thuricin, a narrow spectrum bacteri-
ocin active against Clostridium difficile [141]. In vitro data
suggest a potentially interesting effect as a targeted thera-
py in C. difficile infection. A role on biofilm formation was
also demonstrated [142].
These molecules could potentially be very interesting in
the context of multiresistance based on their broad spec-
trum and lasting effect even on multiresistant strains. Bac-
teriocins are also bactericidal and target Gram-positive as
well as negative pathogens. To date, there is no molecule
available for patients, and well-designed clinical trials are
needed.
Probiotics
Probiotics are live microorganisms that, when adminis-
tered in adequate amounts, confer a health benefit to the
host [143]. The probiotics used are strains of bacteria, usu-
ally Lactobacillus or Bifidobacterium, both of which are
part of the normal gut microbiota, and fungi such as Sac-
charomyces boulardii. Most are marketed as fermented
foods or dairy products or dietary supplements, which can
explain the absence of minimal manufacturing standards
with regulatory oversight as well as the lack of studies
demonstrating health benefits or potential mechanism(s) of
action. Nonetheless, probiotics are used to prevent and/or
treat a wide range of diseases and conditions that affect hu-
mans and animals.
Mechanisms for the benefits of probiotics are still incom-
pletely understood. It is generally presumed that the mol-
ecular mechanisms of probiotics are triggered by so-called
bacterial-epithelial “cross talk”. The activation of the tran-
scription factor nuclear factor κB (NFκB) induces the syn-
thesis of inflammatory cytokines, the basis of an acute
innate inflammatory response. The probiotics have been
shown to interact through four main pathways [144]:
− Antimicrobial activity with the suppression of growth
or expression of bacterial virulence factors. Probiotics pro-
duce both acids that lower the pH of the local environment,
and toxins inhibiting the growth of other bacteria [145],
such as Clostridium difficile.
− Prevention of gastrointestinal tract colonisation by
pathogens: most probiotics temporarily colonise the gut,
producing bactericidal acids and peptides, which promote
“competition” between the probiotic and pathogens such as
C. difficile [146].
− Modulation of the host immune system: probiotics mod-
ulate innate and adaptative immune systems by stimulating
toll-like receptors and up-regulating cytokine expression
in dendritic cells and peripheral blood monocytes. So, the
effects of probiotics on the development of host defense
are generalised mucosal immune response, balanced T-
helper cell response, self-limited inflammatory response,
and polymeric IgA secretion [144].
− Improvement of gastrointestinal barrier integrity: Lacto-
bacillus strains up-regulate mucous genes in intestinal gob-
let cells leading to the activation and the secretion of mu-
cus in the intestine responsible for the inhibition of patho-
genic bacteria attachment to the mucosal barrier [144].
When it comes to potential adverse effects, Lactobacilli,
Lactococci and Bifidobacterium are classified as “general-
ly regarded as safe” [143] based on the long history of ex-
tensive use by millions of individuals and limited side ef-
fects described [147]. Bacteraemia, endocarditis and liver
abscess have been reportedly caused by Lactobacillus spp.
in patients with central venous catheters, intestinal feed-
ing tubes and/or severe comorbidities [147], as well as S.
boulardii fungaemia [148]. Many controlled clinical tri-
als demonstrate that the use of probiotics is safe without
evidence of toxicity (mainly for Lactobacillus) in certain
at-risk populations, such as pregnant women, premature
neonates, elderly or critically ill individuals [147].
Nonetheless, the lack of safety data for certain probiotics in
vulnerable patients calls for cautious use in these members
of the population. Other concerns about toxicity to the gas-
trointestinal tract, precipitating lactic acidosis and/or trans-
fer of antibiotic resistance, remains theoretical without da-
ta reports [147].
In the light of these data, we can wonder what would be the
place of probiotics for the prevention and the treatment of
MDR bacteria. Machairas et al. have shown that intraperi-
toneal pre-treatment with probiotics (Lactobacillus, Sac-
charomyces and Bifidobacterium) significantly prolonged
survival after experimental infection with MDR
Pseudomonas aeruginosa in mice (66.7% vs 31.3%; p =
0.026) by having an effect on sepsis-induced immuno-
suppression (TNFα and IL-10 productions increased, in-
terferon-gamma production decreased, IL-17 production
restored) [149]. One of the major problems regarding an-
tibiotic resistance is the capacity of MDR Gram-negative
bacilli (GNB) or vancomycin-resistant Enterococcus
(VRE) to colonise the gastrointestinal tract of patients for
many months [150], which constitutes a reservoir of MDR
bacteria in hospitals and the community. Moreover, the risk
of infection with MDR bacteria increases in colonised pa-
tients with these bacteria. Thus, one of the strategies of
prevention could be to use probiotics in patients harbor-
ing MDR bacteria for the decolonisation of the gastroin-
testinal tract. In the only randomised double-blind place-
bo-controlled clinical trial to date, probiotics were not ef-
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fective for decolonising hospitalised patients harbouring
MDR GNB [151]. Clinical trials have also been performed
for VRE, but interestingly showed the efficacy of Lacto-
bacillus rhamnosus GG in eradicating VRE carriage [152,
153]. Similarly, probiotics could have a place in the pre-
vention of methicillin-resistant Staphylococcus aureus in-
fections (MRSA) in eliminating this pathogen from the
nasal cavity. Indeed, it is known that S. aureus nasal carri-
ers are three times more at risk of developing nosocomial
bacteraemia than in non-carriers [154] and that S. aureus
carriage eradication by mupirocin is partially efficient with
the possibility of the acquisition of mupirocin resistance.
Non-clinical studies showed that many strains of lacto-
bacilli and bifidobacteria inhibited the growth of S. aureus
and clinical isolates of MRSA in vitro [155]. However,
very little data exist for the clinical use of oral and/or nasal
probiotics in patients with MRSA colonisation. Three
prospective studies showed the elimination of MRSA
colonisation with probiotic use with a decreased incidence
of MRSA infections for one of them [155].
Therefore, probiotics could be important mainly for the
prevention of MDR bacteria infections by modulating the
host immune response, especially in the case of VRE or
MRSA carriage. But clinical trials are needed to evaluate
the efficacy of probiotics for the treatment of MDR infec-
tions.
Faecal microbiota transplantation (FMT)
The gut microbiota is a major player in the host immune re-
sponse to infection, modulating first-line immune players
as well as local and remote response to injury. The role of
faecal microbiota transplantation has already been demon-
strated in Clostridium difficile infection (and specifically
recurrent infections) [156, 157] and this treatment belongs
to the European guidelines for recurrent Clostridium diffi-
cile infection [158]. Interestingly, FMT has also been pro-
posed in other diseases like inflammatory bowel diseases
[159–161], diabetes [162], or obesity [163].
The gut microbiota influences the neutrophilic response to
diverse stimuli. Karmarkar et al. evaluated neutrophilic re-
sponse after an intraperitoneal (i.p.) injection of zymosan,
silica or monosodium urate in germ free or flora-deficient
mice [164]. Their results showed impaired blood extrava-
sation of neutrophils in flora-deficient mice. Neutrophil re-
cruitment required stimulation by microbiota of a myeloid
differentiation primary response gene-88-dependent path-
way (MyD88 is an adaptor molecule of most Toll-like
receptors). In a model of infection by Escherichia coli,
Balmer et al. showed that Toll-like receptor (TLR) sig-
naling was essential for microbiota-driven myelopoiesis
[165]. In a neonatal mouse model, antibiotic exposure at-
tenuated post-natal granulocytosis by reducing IL-17 pro-
ducing cells in the intestine. This relative granulocytopenia
increased the susceptibility of mice to E. coli and Klebsiel-
la pneumoniae sepsis [166].
Locally, gut microbiota participates tresistance to intestinal
pathogens. Ivanov et al. showed that colonisation of the
small intestine with segmented filamentous bacteria (sfb)
increased the frequency of CD4+ T-Helper by producing
IL-17 and IL-22 in the lamina propria [167]. This colonisa-
tion also enhanced resistance to Citrobacter rodentium in-
fection.
The gut microbiota influence the response to injury of re-
mote organs, notably the lung. A seminal work published
in 2011 evaluated the response to respiratory Influenza
virus of mice subjected to 4 weeks’ oral administration of
a combination of antibiotics (vancomycin, metronidazole,
neomycin and ampicillin) [168]. Influenza-virus-specific
antibody titres and CD4 T-cell responses were significant-
ly reduced, while lung viral titer remained significantly el-
evated in antibiotic-treated mice. Consistent with this first
study, Fagundes et al. showed that germ-free mice are
extremely susceptible to an intratracheal challenge of K.
pneumoniae [169]. Priming of mice with TLR agonists re-
stored their resistance to pulmonary infection. These re-
sults show that gut colonisation enables an adapted in-
flammatory response. Similarly, Gauguet et al. showed that
mice lacking intestinal sfb developed a more severe pneu-
monia than mice colonised with sfb when animals were
challenged intranasally with methicillin-resistant Staphy-
lococcus aureus [170]. In this model, the presence of sfb
promoted pulmonary type 17 immunity and resistance to
S. aureus pneumonia, and exogenous IL-22 protected mice
deficient in sfb from S. aureus pneumonia. Using mice de-
pleted or not of gut microbiota with antibiotics and sub-
sequently infected intranasally with Streptococcus pneu-
moniae, Schuijt et al. showed that the gut microbiota pro-
tected against bacterial dissemination, inflammation, organ
damage and mortality [171]. The protective phenotype
conferred by the microbiota was related to enhanced
phagocytosis and cytokine response to lipotechoic acid and
lipopolysaccharide by alveolar macrophages from control
mice when compared to microbiota-depleted mice. Alto-
gether, these results suggest a major role of the “gut-lung”
axis and another way to look at the lung response and po-
tential therapeutic innovative pathways.
In multiresistance, FMT has also been proposed to eradi-
cate colonising antibiotic-resistant bacteria. Bilinski et al.
performed 25 FMT in 20 patients colonised by a median
of 2 strains of antibiotic-resistant bacteria [172]. Decoloni-
sation at 1 month was obtained in 60% of the cases, sug-
gesting that FMT was safe and efficient to eradicate antibi-
otic-resistant bacteria in the subpopulation of patients with
blood disorders included in this study. 10 studies are cur-
rently listed on clinicaltrial.gov that are designed to evalu-
ate FMT in gut colonisation with antibiotic-resistant bacte-
ria.
FMT and all the potential alternatives with synthetic mi-
crobiota could represent an attractive solution for antibi-
otic-resistant bacteria colonisation, but it must be remem-
bered that we only evaluate this short-term endpoint. In
fact, it seems that FMT could clear antibiotic-resistant bac-
teria colonisation earlier than the normal evolution (but
other studies also need to confirm this finding). Several
studies have also shown that gut microbiota was a major
factor associated with the modulation of the host immune
response [173], so any manipulation of the gut microbiota
could potentially be associated with long-term conse-
quences that we must at least monitor in this subgroup of
patients where the vital prognosis is not engaged.
Phage therapy
Among the potential strategies that could be developed
facing multidrug resistance, phage therapy is one of the
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most promising approaches. This “forgotten cure” uses
natural viruses present in all ecosystems that infect specific
bacteria and are unable to infect eukaryote cells.
Discovered in 1915 before penicillin [174], the bacterio-
phage therapy era began after its first use in 1917 by Felix
d‘Herelle [175] and is still commonly used in Eastern Eu-
ropean countries. The lack of data on pharmacokinetics/
pharmacodynamics, immunological response, in vivo effi-
cacy, and emergence of resistance were potential reasons
why this treatment was not developed on a large scale in
other countries a century later.
With a size of 25–200 nm, phages behave like other viruses
with mainly two types of replication cycles: lytic cycle and
lysogenic cycle. The phage penetrates into the bacteria af-
ter attachment then viral nucleic acid (mainly DNA) is re-
leased into the bacterial cytoplasm. During the lytic cy-
cle, the virus uses the host cell’s metabolic machinery to
make large amounts of viral components, and kills bacte-
ria by cellular lysis thanks to phage endolysins, which al-
low the release of progeny virions to infect other bacteria
[176–178]. Temperate phages undergo a lysogenic cycle
during which the viral DNA is quickly integrated into the
bacterial genome or remains in the form of plasmid, and
is then duplicated along with all its genetic material dur-
ing cell division. This new form of viral DNA in dor-
mancy, called “prophage”, can confer specific phenotypic
advantages to the target bacteria, such as resistance or vir-
ulence [176–178]. For these reasons temperate phages are
not considered in phage therapy.
Thus, the development of phage therapy is a promising
way to improve the treatment of MDR bacteria. Indepen-
dently of the administration route (local or systemic),
phages behave as an exponential self-amplifying drug with
in situ increasing concentrations in time. Indeed, the suc-
cess of phage therapy in acute infections is determined not
only by the type of phages and bacteria involved, but also
by the bacterial density at the time of application and the
proliferation kinetic. The timing of treatment is less crucial
in chronic infections where bacteria are abundant. More-
over, beyond their potential efficiency on MDR bacteria,
the impact of phages on the host gut microbiota is insignif-
icant and the antibiotic selection pressure is null thanks
to the narrow specificity towards the bacterial targets and
their mode of action [177]. But this host specificity might
also be a limitation with a risk of treatment failure if the
target is not the bacterium responsible for the infection.
So “broad-spectrum” phages or cocktails containing sever-
al phages targeting different strains of the same pathogen
and/or different bacterial species were mostly used in ther-
apeutics to increase antimicrobial activity and decrease the
risk of phage-resistance development. Finally, one of the
interesting properties of phages is their capacity to hydrol-
yse bacterial polysaccharides forming the biofilm [179].
While antibiotics penetrate with difficulty into biofilms,
phage therapy could therefore play a role for the treatment
of medical devices [178] or diabetic foot infections, or in
cystic fibrosis patients [180], where disease is often caused
by pathogens that are able to produce biofilm (S. aureus or
P. aeruginosa).
Efficacy and safety studies in animals have been per-
formed during the last 20 years and demonstrate most often
the efficacy of phages in different types of infections, in-
cluding pneumonia [181–183], peritonitis, burns, chronic
otitis, orthopaedic implant-related infection [184], bacter-
aemia [185] and more recently endocarditis [186], but also
in the prevention of biofilm production, with different ani-
mal models and several bacteria/phage combinations [185,
186]. In humans, potential applications of phages are both
phage-mediated prevention and phage treatment ranging
from conventional phage therapy, to treatments with phage
enzymes (e.g., endolysins) or combinations of phages with
antibiotics. In theory, most bacterial infections could be
treated by phage therapy, with the exception of strictly in-
tracellular bacteria (no penetration into eukaryote cells),
infections of the central nervous system, and polymicrobial
infections [177]. While several clinical trials have evaluat-
ed the safety of phage therapy in humans for the treatment
of venous leg ulcers [187] or diarrhoeal illness [188, 189],
only a few studies have evaluated its efficacy. Topical
phage therapy was used for the treatment of antibiotic-re-
sistant Pseudomonas aeruginosa chronic otitis, a difficult-
to-treat infection due to biofilm production. In a prospec-
tive randomised double-blind phase I/II trial, phage ther-
apy improved clinical outcomes significantly and reduced
bacterial counts without side effects [190]. In a randomised
study evaluating oral phage therapy in enterotoxigenic and
enteropathogenic E. coli – diarrhoea versus placebo in 120
children in Bangladesh, oral coliphages were safe but did
not improve diarrhoea outcome, possibly due to the insuf-
ficient phage coverage and low phage doses [189]. Like-
wise, a recent case report showed the efficiency of bac-
teriophage monotherapy in the treatment of colistin-only
sensitive P. aeruginosa bacteraemia in a patient with acute
kidney injury [191]. Several multicentre, randomised con-
trolled phase I/II trials of phage therapy are currently being
held for the treatment of wound infections by E. coli and
P. aeruginosa in burned patients (PHAGOBURN), in S.
epidermidis and S. aureus bone and joints infections
(PHOSA) or S. aureus diabetic foot ulcers infected
(PHAGOPIED).
Bacteriophage resistance can appear by various mecha-
nisms [192] during treatment, but the clinical impact is still
not well studied [177].
Finally, understanding the interaction between bacterio-
phages and host immunity is essential for the rational use
of this treatment. No tolerance issue was observed in pre-
vious studies when the preparation of phages, which were
rich in bacterial degradation products and strongly im-
munogenic, were cleansed. Adaptative immunity can also
be involved in the clearance of phages via the production
of specific neutralising antiphage antibodies [193], in-
duced by the phages themselves, but without consequences
for the efficacy of phage therapy and the outcome of infec-
tions [194, 195].
Thus, phage therapy is not a universal therapeutic weapon
but a future major ally against MDR bacteria that requires
more research, as concluded by N. Dufour and L. Debarbi-
eux in their review of phage therapy [177]. Phage therapy
could potentially be very interesting in the context of multi
resistance based on their broad spectrum, their in situ in-
creasing concentrations in time, and their capacity to treat
biofilm-related infections. To date, there are currently no
phage applications for humans approved in the world, but
phage therapy could be a safe alternative or association to
antibiotic therapy [186, 196] in the context of MDR, and
clinical trials are needed.
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Table 1: Advantages and limitations of non-antibiotic approaches.
Target Approach Advantages Limitations
Combination Circumvent resistance mechanisms
Revival of old molecules
Cumulated toxicity
Difficulty to build randomised trial
Evolution of resistance
New drugs Adapted spectrum Limited number
Cost
Antibodies against virulence fac-
tors
Targeted therapy Specific to a single factor/pathogen
Requires diagnostic specificity
Cost
Quorum sensing inhibition Focused on virulence factors Lack of strong clinical proof
Bacteriocins Direct action on the bacteria
Low probability of resistance
No clinical trial
Pharmacokinetic/-dynamic parameters unknown
Bacteria
Phage therapy Specific of the bacteria
Preservation of the microbiota
Can be used topically
Catalogue of phage available
Cost
Mimited number of clinical proof
Pharmacokinetic/-dynamic parameters unknown
Requires diagnostic specificity
Antibodies in sepsis Targeted therapy
Not pathogen specific
Production
Cost
Not directly related to resistance
A lot of failure in the past
Probiotics Available
Cost
No clinical trial
Host response
Faecal microbiota transplantation Cost Long term effect
Limited number of clinical proof
Conclusion
In this review, we have presented several potential treat-
ments that could be proposed in the case of multiresistant
pathogens (table 1). Antibiotic combination will probably
remain a valid option for a limited time. The fact that bac-
terial plasticity evolves under pressure is largely beyond
our control. Similarly for antibodies, the window of op-
portunity in quite narrow and the potential for bacteria to
associate different virulence mechanisms make the task of
proposing a unique target very difficult. Manipulation of
the microbiota is a real option but stands more in the pre-
ventive than curative area, and the long-term consequences
constitute a major threat in the context of resistance. Fi-
nally, phages are a really attractive therapy but require an
important infrastructure. Globally we have numerous dif-
ferent pathways but all of them still need well-construct-
ed prospective studies, which are nowadays difficult to
achieve. A lot of things can be done without new drugs, but
the best path is to avoid the emergence of resistance and
preserve our new as well as our old molecules.
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